Johnson & Johnson (JNJ)
Johnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble
Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.
J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business
Johnson & Johnson is “leaning” toward spinning out the hips-and-knees business that the company has been looking to hive off, Chief Financial Officer Joseph Wolk said.
Treasury Bills vs Dividend Stocks: Which Income Stream Actually Fits Your Retirement
Treasury bills guarantee your rate until maturity while Johnson and Johnson has raised its dividend for 64 straight years, but depending on your tax state and timeline, one of these income streams quietly keeps far more money in your pocket
Here's How Much Johnson & Johnson Stock Is Expected to Move After Earnings
Johnson & Johnson is due to report earnings Tuesday morning, with traders expecting a move that could bring the stock closer to its recent record.
Wells Fargo, Bank of America, Domino's, Johnson & Johnson, Inflation Data, and More to Watch This Week
Big bank earnings arrive, with Citi, Goldman Sachs, JPMorgan Chase, and more reporting. Consumer and producer price indexes and existing home sales data will provide a read on the economy.
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
JNJ heads into Q3 earnings with strong drug sales and new launches, but Stelara biosimilar competition and MedTech challenges could weigh on growth.
4 Dividend Stocks Boomers Can Safely Buy Now and Hold Forever
Four Dividend Kings with streaks stretching back decades sit inside millions of retirement portfolios, but one of them is spending every dollar of free cash flow just to keep its streak alive.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Besides Wall Street's top-and-bottom-line estimates for Johnson & Johnson (JNJ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
These 5 Dividend Stocks Are Americas Favorite Companies
Procter and Gamble has raised its dividend every year for seven decades, and it is not even the highest-yielding name on this list. These five household giants reveal just how differently income investors can play the same dividend-safety game.
Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?
Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying the stock right now.
